Edratide

• CAT Number: I042541
• CAS Number: 433922-67-9
• Molecular Formula: C111H149N27O28
• Molecular Weight: 2309.53
• Purity: ≥95%

Edratide (Cat No.: I042541) is a synthetic peptide derived from the complementarity-determining region (CDR1) of a human anti-DNA monoclonal antibody, developed as an immunomodulatory therapy for systemic lupus erythematosus (SLE). It aims to restore immune tolerance by downregulating autoreactive T cells and modulating cytokine profiles without broad immunosuppression. Edratide has shown potential in reducing disease activity and improving serological markers in preclinical and early clinical studies. It represents a targeted therapeutic approach designed to treat autoimmune conditions with greater specificity and fewer side effects.

Reference

[1]. Urowitz MB, et al. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. Lupus Sci Med. 2015 Aug 11;2(1):e000104.
[Content Brief]

[2]. Elmann A, et al. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 2007 Jul;56(7):2371-81.
[Content Brief]

[3]. Sharabi A, et al. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007 Oct 15;179(8):4979-87.
[Content Brief]